Endoscopic remission

When a camera test (colonoscopy or similar) shows the bowel lining no longer has active inflammation or ulcers.

Also called: endoscopic healing, endoscopic response, healed bowel, bowel healing

Related words mucosal healing deep remission

Topics Research Monitoring

Questions people ask

What does 'treat to target' mean?

It means your team agrees goals in advance and adjusts treatment until you reach them, rather than waiting for symptoms. The STRIDE-II expert agreement says early goals are feeling better and getting blood and poo inflammation tests back to normal; longer-term goals are a healed bowel lining, no disability, good quality of life and normal growth in children. The CALM trial found that stepping up treatment when tests showed inflammation, not just when symptoms flared, led to more bowel healing.

Sources

What do 'flare-up' and 'remission' mean?

Crohn's usually comes and goes. Crohn's & Colitis UK describes remission as a time when Crohn's is well controlled, you feel better and tests show less inflammation, although some symptoms like tiredness may linger. A flare-up (also called a relapse or active disease) is when symptoms return and tests show the gut is inflamed. The NHS says a flare can last from a few days to several months.

Sources

Which biologic is best for Crohn's?

There is no single best biologic for everyone. Trials comparing two drugs directly are still few: SEAVUE found ustekinumab and adalimumab worked about equally well in people new to biologics, and SEQUENCE found risankizumab was better than ustekinumab at healing the bowel in people for whom anti-TNF drugs had not worked. A 2026 Cochrane review comparing all the options says more head-to-head trials are needed.

Sources

What is the CDAI, and how is it different from the HBI?

The Crohn's Disease Activity Index (CDAI) is an older, longer score. It needs a 7-day symptom diary, your weight and a blood test result, so it takes more effort to work out. A CDAI under 150 is taken as a marker of remission and over 450 as a marker of severe Crohn's. The Harvey-Bradshaw Index is a simpler score based on just the previous day's symptoms and does not need a blood test.

Sources

Why am I so tired all the time with Crohn's?

Fatigue is one of the commonest Crohn's symptoms. Crohn's & Colitis UK says it affects around 7 in 10 people during a flare and around 4 in 10 in remission, and has many possible causes. Anaemia from blood loss or poor absorption is one of them, so a blood test is worth asking about. A Cochrane review found only weak evidence so far for specific fatigue treatments.

Sources

Where to read more

British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025

British Society of Gastroenterology Guideline Jun 2025 For professionals

The current UK specialist guideline for managing IBD in adults, replacing the 2019 version. It is designed to sit alongside the IBD Standards and encourage use of the national primary care pathway for lower gut symptoms so diagnosis is quicker and more accurate. Among its general principles, it recommends classifying Crohn's using the Montreal system.

Topics About Crohn's disease Diagnosis and tests Medicines Monitoring Complications Surgery

Jargon explained Montreal classification remission endoscopic remission inflammatory bowel disease advanced therapy GRADE induction maintenance

Management of pediatric Crohn's disease: an ECCO-ESPGHAN guideline update

ECCO and ESPGHAN (J Crohns Colitis) Guideline Aug 2026 For professionals

The newest European guideline for children with Crohn's, agreed by 27 experts. Children at high risk of a difficult course should start an anti-TNF biologic first, with blood-level checks of the drug. For lower-risk children, a liquid-only diet (EEN) or the Crohn's Disease Exclusion Diet with partial liquid feeds are the preferred first treatments. Long-term goals include a healed bowel lining, normal growth and a good quality of life.

Topics Children and young people Diet and nutrition Biologics and newer medicines Monitoring

Jargon explained anti-TNF therapeutic drug monitoring exclusive enteral nutrition endoscopic remission

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD)

Gastroenterology Guideline Apr 2021 For professionals

An international expert agreement on what 'treat to target' should aim for in IBD. Short-term goals are feeling better and getting blood and poo inflammation tests back to normal. Long-term goals include a healed bowel lining seen at endoscopy, no disability, a normal quality of life, and normal growth in children. Healing through the full bowel wall in Crohn's is not yet a formal target but is a sign of deeper remission.

Topics Monitoring Research Medicines

Jargon explained treat to target endoscopic healing transmural healing biomarker calprotectin CRP clinical remission

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE)

New England Journal of Medicine Study Jul 2024 Patients and professionals

A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.

Topics Biologics and newer medicines Research

Jargon explained non-inferiority endoscopic remission anti-TNF

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

The Lancet Study May 2022 Patients and professionals

Two trials testing risankizumab (Skyrizi) drips to bring active Crohn's under control, including in people for whom other biologics had failed. Risankizumab led to more remissions, and more improvement seen on camera tests of the bowel, at 12 weeks than placebo, and was generally well tolerated.

Topics Biologics and newer medicines

Jargon explained induction phase 3 trial endoscopic response

Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE)

New England Journal of Medicine Study May 2023 Patients and professionals

Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.

Topics Medicines Immunosuppressants Research

Jargon explained JAK inhibitor small molecule induction maintenance herpes zoster endoscopic response

The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD)

The Lancet Gastroenterology & Hepatology Study Jan 2022 Patients and professionals

A small pilot trial of 44 adults with mild to moderate Crohn's who had not had biologics. The CDED, with or without supplement drinks, put more than half into remission at 6 weeks, and most of them were still in remission at 24 weeks. About a third had a healed bowel lining. The authors say a bigger trial is needed before firm conclusions.

Topics Diet and nutrition

Jargon explained pilot study open-label endoscopic remission

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease (FORTIFY)

The Lancet Study May 2022 For professionals

The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.

Topics Biologics and newer medicines Research

Jargon explained IL-23 maintenance placebo endoscopic response

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review

Journal of Crohn's and Colitis via PubMed Central Systematic review Feb 2020 For professionals

Reviews the evidence for 'treat to target', where treatment is adjusted not just to symptoms but to measured goals such as a healed bowel lining and normal blood or poo markers. It explains the idea behind the STRIDE targets and notes that firm proof that aiming for healing improves long-term outcomes was still emerging.

Topics Monitoring Research

Jargon explained treat to target mucosal healing biomarker STRIDE

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

The Lancet Study Dec 2017 Patients and professionals

CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.

Topics Monitoring Biologics and newer medicines Research

Jargon explained tight control faecal calprotectin CRP mucosal healing treat to target

Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Cochrane Systematic review Sep 2019 Patients and professionals

Compares the medicines used to stop Crohn's returning after an operation. The evidence was not strong enough to say which works best. Cases of pancreatitis and low white blood cell counts were seen with azathioprine-type drugs.

Topics Surgery Medicines

Jargon explained network meta-analysis endoscopic relapse postoperative recurrence

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

Gastroenterology Study Jan 2007 Patients and professionals

The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.

Topics Biologics and newer medicines

Jargon explained maintenance remission CDAI placebo

Search everything for "endoscopic remission"